Gilead Sciences NASDAQ: GILD has filed 13-F forms with the SEC as an investor. Gilead Sciences is itself a publicly traded company. Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. For more information on Gilead Sciences stock, visit the Gilead Sciences stock profile here.
Investment Activity
- Gilead Sciences has $1.18 billion in total holdings as of March 31, 2025.
- Gilead Sciences owns shares of 14 different stocks, but just 3 companies or ETFs make up 80% of its holdings.
- Approximately 1.40% of the portfolio was purchased this quarter.
- About 0.77% of the portfolio was sold this quarter.
- This quarter, Gilead Sciences has purchased 16 new stocks and bought additional shares in 1 stock.
- Gilead Sciences sold shares of 2 stocks and completely divested from 3 stocks this quarter.
Largest Holdings
- ASSEMBLY BIOSCIENCES INC
- $21,122,543
Largest New Holdings this Quarter
- 482929106 - KALARIS THERAPEUTICS INC
- $5,807,882 Holding
Largest Purchases this Quarter
- KALARIS THERAPEUTICS INC
- 723,273 shares (about $5.81M)
Largest Sales this Quarter
